JPWO2020061177A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020061177A5 JPWO2020061177A5 JP2021515578A JP2021515578A JPWO2020061177A5 JP WO2020061177 A5 JPWO2020061177 A5 JP WO2020061177A5 JP 2021515578 A JP2021515578 A JP 2021515578A JP 2021515578 A JP2021515578 A JP 2021515578A JP WO2020061177 A5 JPWO2020061177 A5 JP WO2020061177A5
- Authority
- JP
- Japan
- Prior art keywords
- rnai agent
- seq
- disease
- nucleotide sequence
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000009368 gene silencing by RNA Effects 0.000 claims description 58
- 239000003795 chemical substances by application Substances 0.000 claims description 55
- 102100037429 17-beta-hydroxysteroid dehydrogenase 13 Human genes 0.000 claims description 33
- 101000806241 Homo sapiens 17-beta-hydroxysteroid dehydrogenase 13 Proteins 0.000 claims description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 25
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 21
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 230000000692 anti-sense effect Effects 0.000 claims description 12
- 230000014509 gene expression Effects 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 108091081021 Sense strand Proteins 0.000 claims description 8
- 101150000579 Hsd17b13 gene Proteins 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 4
- 208000019423 liver disease Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 108091030071 RNAI Proteins 0.000 claims 25
- 125000003729 nucleotide group Chemical group 0.000 claims 18
- 239000002773 nucleotide Substances 0.000 claims 10
- SXUXMRMBWZCMEN-UHFFFAOYSA-N 2'-O-methyl uridine Natural products COC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-UHFFFAOYSA-N 0.000 claims 8
- FPUGCISOLXNPPC-IOSLPCCCSA-N cordysinin B Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2N=C1 FPUGCISOLXNPPC-IOSLPCCCSA-N 0.000 claims 8
- 239000000126 substance Substances 0.000 claims 8
- QPHRQMAYYMYWFW-FJGDRVTGSA-N 1-[(2r,3s,4r,5r)-3-fluoro-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 QPHRQMAYYMYWFW-FJGDRVTGSA-N 0.000 claims 4
- FPUGCISOLXNPPC-UHFFFAOYSA-N 2'-O-Methyladenosine Natural products COC1C(O)C(CO)OC1N1C2=NC=NC(N)=C2N=C1 FPUGCISOLXNPPC-UHFFFAOYSA-N 0.000 claims 4
- RFCQJGFZUQFYRF-UHFFFAOYSA-N 2'-O-Methylcytidine Natural products COC1C(O)C(CO)OC1N1C(=O)N=C(N)C=C1 RFCQJGFZUQFYRF-UHFFFAOYSA-N 0.000 claims 4
- OVYNGSFVYRPRCG-UHFFFAOYSA-N 2'-O-Methylguanosine Natural products COC1C(O)C(CO)OC1N1C(NC(N)=NC2=O)=C2N=C1 OVYNGSFVYRPRCG-UHFFFAOYSA-N 0.000 claims 4
- RFCQJGFZUQFYRF-ZOQUXTDFSA-N 2'-O-methylcytidine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1 RFCQJGFZUQFYRF-ZOQUXTDFSA-N 0.000 claims 4
- OVYNGSFVYRPRCG-KQYNXXCUSA-N 2'-O-methylguanosine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=C(N)NC2=O)=C2N=C1 OVYNGSFVYRPRCG-KQYNXXCUSA-N 0.000 claims 4
- SXUXMRMBWZCMEN-ZOQUXTDFSA-N 2'-O-methyluridine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-ZOQUXTDFSA-N 0.000 claims 4
- PJWBTAIPBFWVHX-FJGDRVTGSA-N 4-amino-1-[(2r,3s,4r,5r)-3-fluoro-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@](F)(O)[C@H](O)[C@@H](CO)O1 PJWBTAIPBFWVHX-FJGDRVTGSA-N 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 230000008685 targeting Effects 0.000 claims 4
- UUDVSZSQPFXQQM-GIWSHQQXSA-N (2r,3s,4r,5r)-2-(6-aminopurin-9-yl)-3-fluoro-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@]1(O)F UUDVSZSQPFXQQM-GIWSHQQXSA-N 0.000 claims 3
- BGTXMQUSDNMLDW-AEHJODJJSA-N 2-amino-9-[(2r,3s,4r,5r)-3-fluoro-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@]1(O)F BGTXMQUSDNMLDW-AEHJODJJSA-N 0.000 claims 3
- BXJSAMKIFDDLGI-UHFFFAOYSA-N 2-(dimethylamino)-N-[2-[3-[[5-[3-(dimethylcarbamoyl)phenyl]-2-methoxyphenyl]sulfonylamino]anilino]ethyl]benzamide Chemical compound COc1ccc(cc1S(=O)(=O)Nc1cccc(NCCNC(=O)c2ccccc2N(C)C)c1)-c1cccc(c1)C(=O)N(C)C BXJSAMKIFDDLGI-UHFFFAOYSA-N 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- KKZFLSZAWCYPOC-VPENINKCSA-N Deoxyribose 5-phosphate Chemical group O[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 KKZFLSZAWCYPOC-VPENINKCSA-N 0.000 claims 2
- 125000003158 alcohol group Chemical group 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- RHLMXWCISNJNDH-UHFFFAOYSA-N n-[2-[3-[[5-[3-(dimethylcarbamoyl)phenyl]-2-methoxyphenyl]sulfonylamino]anilino]ethyl]-3-methylbenzamide Chemical compound COC1=CC=C(C=2C=C(C=CC=2)C(=O)N(C)C)C=C1S(=O)(=O)NC(C=1)=CC=CC=1NCCNC(=O)C1=CC=CC(C)=C1 RHLMXWCISNJNDH-UHFFFAOYSA-N 0.000 claims 2
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 33
- 208000019425 cirrhosis of liver Diseases 0.000 description 28
- 230000007882 cirrhosis Effects 0.000 description 15
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 14
- 230000001476 alcoholic effect Effects 0.000 description 14
- 230000000069 prophylactic effect Effects 0.000 description 10
- 206010016654 Fibrosis Diseases 0.000 description 8
- 238000010254 subcutaneous injection Methods 0.000 description 6
- 239000007929 subcutaneous injection Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 101710194118 17-beta-hydroxysteroid dehydrogenase 13 Proteins 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Images
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024076157A JP7741927B2 (ja) | 2018-09-19 | 2024-05-08 | １７β－ＨＳＤ１３型（ＨＳＤ１７Ｂ１３）の発現を阻害するためのＲＮＡｉ剤、その組成物、および使用方法 |
| JP2025147403A JP2025186315A (ja) | 2018-09-19 | 2025-09-05 | １７β－ＨＳＤ１３型（ＨＳＤ１７Ｂ１３）の発現を阻害するためのＲＮＡｉ剤、その組成物、および使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862733320P | 2018-09-19 | 2018-09-19 | |
| US62/733,320 | 2018-09-19 | ||
| US201862773707P | 2018-11-30 | 2018-11-30 | |
| US62/773,707 | 2018-11-30 | ||
| US201962890220P | 2019-08-22 | 2019-08-22 | |
| US62/890,220 | 2019-08-22 | ||
| PCT/US2019/051707 WO2020061177A1 (en) | 2018-09-19 | 2019-09-18 | Rnai agents for inhibiting expression of 17beta-hsd type 13- (hsd17b13), compositions thereof, and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024076157A Division JP7741927B2 (ja) | 2018-09-19 | 2024-05-08 | １７β－ＨＳＤ１３型（ＨＳＤ１７Ｂ１３）の発現を阻害するためのＲＮＡｉ剤、その組成物、および使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022501040A JP2022501040A (ja) | 2022-01-06 |
| JPWO2020061177A5 true JPWO2020061177A5 (enExample) | 2023-11-24 |
| JP7488254B2 JP7488254B2 (ja) | 2024-05-21 |
Family
ID=69887755
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021515578A Active JP7488254B2 (ja) | 2018-09-19 | 2019-09-18 | １７β－ＨＳＤ１３型（ＨＳＤ１７Ｂ１３）の発現を阻害するためのＲＮＡｉ剤、その組成物、および使用方法 |
| JP2024076157A Active JP7741927B2 (ja) | 2018-09-19 | 2024-05-08 | １７β－ＨＳＤ１３型（ＨＳＤ１７Ｂ１３）の発現を阻害するためのＲＮＡｉ剤、その組成物、および使用方法 |
| JP2025147403A Pending JP2025186315A (ja) | 2018-09-19 | 2025-09-05 | １７β－ＨＳＤ１３型（ＨＳＤ１７Ｂ１３）の発現を阻害するためのＲＮＡｉ剤、その組成物、および使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024076157A Active JP7741927B2 (ja) | 2018-09-19 | 2024-05-08 | １７β－ＨＳＤ１３型（ＨＳＤ１７Ｂ１３）の発現を阻害するためのＲＮＡｉ剤、その組成物、および使用方法 |
| JP2025147403A Pending JP2025186315A (ja) | 2018-09-19 | 2025-09-05 | １７β－ＨＳＤ１３型（ＨＳＤ１７Ｂ１３）の発現を阻害するためのＲＮＡｉ剤、その組成物、および使用方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US12534728B2 (enExample) |
| EP (1) | EP3852769A4 (enExample) |
| JP (3) | JP7488254B2 (enExample) |
| KR (1) | KR102769565B1 (enExample) |
| CN (1) | CN113164509A (enExample) |
| AU (1) | AU2019342117A1 (enExample) |
| BR (1) | BR112021005137A2 (enExample) |
| CA (1) | CA3109553A1 (enExample) |
| CL (1) | CL2021000669A1 (enExample) |
| CO (1) | CO2021003446A2 (enExample) |
| CR (1) | CR20210186A (enExample) |
| EC (1) | ECSP21027262A (enExample) |
| IL (1) | IL281597A (enExample) |
| MX (1) | MX2021003077A (enExample) |
| MY (1) | MY209138A (enExample) |
| PE (1) | PE20211212A1 (enExample) |
| PH (1) | PH12021550423A1 (enExample) |
| SG (1) | SG11202101698WA (enExample) |
| TW (2) | TW202540423A (enExample) |
| UY (1) | UY38382A (enExample) |
| WO (1) | WO2020061177A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116832169A (zh) * | 2016-09-02 | 2023-10-03 | 箭头药业股份有限公司 | 靶向配体 |
| AU2019239971B2 (en) | 2018-03-21 | 2025-09-11 | Regeneron Pharmaceuticals, Inc. | 17beta-hydroxysteroid dehydrogenase type 13 (HSD17b13) iRNA compositions and methods of use thereof |
| CA3109553A1 (en) * | 2018-09-19 | 2020-03-26 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of 17beta-hsd type 13 (hsd17b13), compositions thereof, and methods of use |
| SG11202106378VA (en) * | 2018-12-21 | 2021-07-29 | Ionis Pharmaceuticals Inc | Modulators of hsd17b13 expression |
| IL298697A (en) * | 2020-06-01 | 2023-02-01 | Amgen Inc | Rnai constructs for inhibiting hsd17b13 expression and methods of use thereof |
| WO2022098748A1 (en) * | 2020-11-06 | 2022-05-12 | Inipharm, Inc. | Uses for hsd17b13 inhibitors |
| WO2022140624A1 (en) | 2020-12-23 | 2022-06-30 | Regeneron Pharmaceuticals, Inc. | Treatment of liver diseases with cell death inducing dffa like effector b (cideb) inhibitors |
| CA3216332A1 (en) * | 2021-04-22 | 2022-10-27 | Tuojie Biotech (Shanghai) Co., Ltd. | Sirna targeting 17b-hydroxysteroid dehydrogenase type 13 and sirna conjugate |
| CN118103038A (zh) | 2021-08-20 | 2024-05-28 | 英安塔制药有限公司 | 17β-羟基类固醇脱氢酶13型抑制剂及其使用方法 |
| KR20240053635A (ko) * | 2021-09-08 | 2024-04-24 | 알리고스 테라퓨틱스 인코포레이티드 | 변형된 짧은 간섭 핵산 (sina) 분자 및 그의 용도 |
| IL312743A (en) * | 2021-11-18 | 2024-07-01 | Novartis Ag | Compounds targeting PMP22 for the treatment of Charcot-Marie-Shen disease |
| EP4433596A4 (en) * | 2021-11-19 | 2026-02-11 | Wave Life Sciences Ltd | DOUBLE-STRANDED OLIGONUCLETIC COMPOSITIONS ASSOCIATED WITH HSD17B13 AND RELATED PROCESSES |
| WO2023109935A1 (zh) * | 2021-12-16 | 2023-06-22 | 上海拓界生物医药科技有限公司 | 一种dsRNA、其制备方法及应用 |
| MX2024007463A (es) | 2021-12-20 | 2024-09-02 | Regeneron Pharma | Metodos para identificar y evaluar la inflamacion hepatica y la fibrosis hepatica en un sujeto mediante la determinacion de una puntuacion estratificada basada en la expresion genetica. |
| CN118541487A (zh) * | 2022-01-20 | 2024-08-23 | 上海拓界生物医药科技有限公司 | 一种dsRNA、其应用及制备方法 |
| US20250283089A1 (en) | 2022-04-08 | 2025-09-11 | Arrowhead Pharmaceuticals, Inc. | Treatment of a non-alcoholic fatty liver disease |
| JP2025516002A (ja) * | 2022-04-28 | 2025-05-23 | エナンタ ファーマシューティカルズ インコーポレイテッド | ピリミジノン含有１７－ベータ－ヒドロキシステロイドデヒドロゲナーゼ１３型阻害剤 |
| CN116515835A (zh) * | 2022-04-29 | 2023-08-01 | 北京福元医药股份有限公司 | 用于抑制HSD17B13表达的siRNA、其缀合物和药物组合物及其用途 |
| WO2023213284A1 (zh) * | 2022-05-06 | 2023-11-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2024131916A1 (en) * | 2022-12-22 | 2024-06-27 | Shanghai Argo Biopharmaceutical Co., Ltd. | Compositions and methods for inhibiting expression of 17beta-hydroxysteroid dehydrogenase type 13 (hsd17b13) |
| CN118773194A (zh) * | 2023-06-16 | 2024-10-15 | 施能康医药科技(苏州)有限公司 | 靶向17-β-羟基类固醇脱氢酶13的核酸及其用途 |
| WO2025049773A1 (en) * | 2023-08-30 | 2025-03-06 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of inhibin subunit beta e (inhbe), pharmaceutical compositions thereof, and methods of use |
| WO2025076225A1 (en) * | 2023-10-04 | 2025-04-10 | Enanta Pharmaceuticals, Inc. | 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof |
| WO2025074157A1 (en) | 2023-10-06 | 2025-04-10 | Glaxosmithkline Intellectual Property (No.3) Limited | Treatment of a non-alcoholic fatty liver disease |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
| US5624813A (en) | 1994-04-21 | 1997-04-29 | Mahant; Vijay K. | NAD(P)+ /NAD(P)H based chemiluminescent diagnostics |
| WO1997020942A1 (en) | 1995-12-05 | 1997-06-12 | Piao Yun Shang | Hsd17b1 promoter, enhancer, silencer and use thereof |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US6391311B1 (en) | 1998-03-17 | 2002-05-21 | Genentech, Inc. | Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1 |
| WO2000053722A2 (en) | 1999-03-10 | 2000-09-14 | Phogen Limited | Delivery of nucleic acids and proteins to cells |
| FR2801218B1 (fr) | 1999-11-23 | 2001-12-28 | Hoechst Marion Roussel Inc | Compositions pharmaceutiques comprenant de la trimegestone, leurs procedes de preparation ainsi que le conditionnement primaire les renfermant |
| WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| US8090542B2 (en) | 2002-11-14 | 2012-01-03 | Dharmacon Inc. | Functional and hyperfunctional siRNA |
| US7754709B2 (en) | 2003-06-10 | 2010-07-13 | Solvay Pharmaceuticals Bv | Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds |
| US20080299042A1 (en) | 2004-04-30 | 2008-12-04 | Biogen Idec Ma Inc. | Membrane Associated Molecules |
| AU2005248147A1 (en) | 2004-05-11 | 2005-12-08 | Alphagen Co., Ltd. | Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same |
| FR2904000A1 (fr) | 2006-07-19 | 2008-01-25 | Galderma Res & Dev S N C Snc | Modulateurs de hsd17b7 dans le traitement de l'acne ou de l'hyperseborrhee |
| CN101500548A (zh) | 2006-08-18 | 2009-08-05 | 弗·哈夫曼-拉罗切有限公司 | 用于体内递送多核苷酸的多缀合物 |
| US20100056384A1 (en) | 2008-09-04 | 2010-03-04 | Board Of Regents, The University Of Texas System | Sequence Variations in PNPLA3 Associated with Hepatic Steatosis |
| SG183374A1 (en) | 2010-02-24 | 2012-09-27 | Arrowhead Res Corp | Compositions for targeted delivery of sirna |
| AU2011302152B2 (en) | 2010-09-15 | 2015-06-11 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
| DK2632472T3 (en) | 2010-10-29 | 2018-03-19 | Sirna Therapeutics Inc | RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA) |
| US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| HK1199736A1 (en) | 2011-08-26 | 2015-07-17 | 箭头研究公司 | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
| WO2013158141A1 (en) | 2012-04-18 | 2013-10-24 | Arrowhead Research Corporation | Poly(acrylate) polymers for in vivo nucleic acid delivery |
| WO2013177060A2 (en) | 2012-05-20 | 2013-11-28 | Trustees Of Boston University | Methods and systems for monitoring, diagnosing, and treating chronic obstructive polmonary disease |
| US20150147761A1 (en) | 2012-06-20 | 2015-05-28 | Helmut E. Meyer | Specific biomarkers for hepatocellular carcinoma (hcc) |
| CN103520724B (zh) | 2013-10-23 | 2016-05-25 | 江苏美迪森生物医药有限公司 | Hsd17b13蛋白或其编码基因的抑制剂的新用途 |
| CA2954791C (en) | 2014-07-14 | 2025-11-18 | The Regents Of The University Of California | CRISPR/CAS TRANSCRIPTIONAL MODULATION |
| CN107250362B (zh) * | 2014-11-17 | 2021-10-22 | 阿尔尼拉姆医药品有限公司 | 载脂蛋白C3(APOC3)iRNA组合物及其使用方法 |
| CN104698108B (zh) | 2015-03-26 | 2016-11-09 | 中国药科大学 | 一种利用固定化酶筛选I型17β羟类固醇脱氢酶抑制剂的方法 |
| WO2017048620A1 (en) | 2015-09-14 | 2017-03-23 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof |
| JOP20210043A1 (ar) * | 2015-10-01 | 2017-06-16 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| MX2018009854A (es) * | 2016-03-07 | 2018-11-09 | Arrowhead Pharmaceuticals Inc | Ligandos dirigidos para compuestos terapeuticos. |
| CN116832169A (zh) | 2016-09-02 | 2023-10-03 | 箭头药业股份有限公司 | 靶向配体 |
| CA3045134A1 (en) | 2016-12-14 | 2018-06-21 | Ligandal, Inc. | Compositions and methods for nucleic acid and/or protein payload delivery |
| MX2019008252A (es) | 2017-01-10 | 2019-09-06 | Arrowhead Pharmaceuticals Inc | Agentes de interferencia de acido ribonucleico (iarn) de alfa-1 antitripsina (aat), composiciones que incluyen agentes de iarn aat y metodos de uso. |
| WO2018136758A1 (en) * | 2017-01-23 | 2018-07-26 | Regeneron Pharmaceuticals, Inc. | Hsd17b13 variants and uses thereof |
| US10533256B2 (en) | 2017-10-09 | 2020-01-14 | GKN Aerospace Transparency Systems, Inc. | Hydrophobic coatings for metals incorporating anodic and rare-earth oxides and methods of applying same |
| JP7434151B2 (ja) | 2017-10-11 | 2024-02-20 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｐｎｐｌａ３ ｉ１４８ｍの変異を発現している患者の肝疾患の治療におけるｈｓｄ１７ｂ１３の阻害 |
| AU2019239971B2 (en) * | 2018-03-21 | 2025-09-11 | Regeneron Pharmaceuticals, Inc. | 17beta-hydroxysteroid dehydrogenase type 13 (HSD17b13) iRNA compositions and methods of use thereof |
| CA3093547A1 (en) | 2018-03-21 | 2019-09-26 | Ionis Pharmaceuticals, Inc. | Modulation of hsd17b13 expression |
| CA3109553A1 (en) | 2018-09-19 | 2020-03-26 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of 17beta-hsd type 13 (hsd17b13), compositions thereof, and methods of use |
| WO2023220561A1 (en) * | 2022-05-09 | 2023-11-16 | Sanegene Bio Usa Inc. | Double stranded rna targeting 17-beta hydroxysteroiddehydrogenase 13 (hsd17b13) and methods of use thereof |
-
2019
- 2019-09-18 CA CA3109553A patent/CA3109553A1/en active Pending
- 2019-09-18 EP EP19861799.5A patent/EP3852769A4/en active Pending
- 2019-09-18 CN CN201980061674.3A patent/CN113164509A/zh active Pending
- 2019-09-18 AU AU2019342117A patent/AU2019342117A1/en active Pending
- 2019-09-18 US US17/275,959 patent/US12534728B2/en active Active
- 2019-09-18 CR CR20210186A patent/CR20210186A/es unknown
- 2019-09-18 PE PE2021000332A patent/PE20211212A1/es unknown
- 2019-09-18 MY MYPI2021001377A patent/MY209138A/en unknown
- 2019-09-18 SG SG11202101698WA patent/SG11202101698WA/en unknown
- 2019-09-18 JP JP2021515578A patent/JP7488254B2/ja active Active
- 2019-09-18 BR BR112021005137-6A patent/BR112021005137A2/pt unknown
- 2019-09-18 MX MX2021003077A patent/MX2021003077A/es unknown
- 2019-09-18 WO PCT/US2019/051707 patent/WO2020061177A1/en not_active Ceased
- 2019-09-18 KR KR1020217011047A patent/KR102769565B1/ko active Active
- 2019-09-19 TW TW113149493A patent/TW202540423A/zh unknown
- 2019-09-19 TW TW108133764A patent/TWI870358B/zh active
- 2019-09-19 UY UY0001038382A patent/UY38382A/es active IP Right Grant
-
2021
- 2021-02-28 PH PH12021550423A patent/PH12021550423A1/en unknown
- 2021-03-17 IL IL281597A patent/IL281597A/en unknown
- 2021-03-17 CO CONC2021/0003446A patent/CO2021003446A2/es unknown
- 2021-03-18 CL CL2021000669A patent/CL2021000669A1/es unknown
- 2021-04-19 EC ECSENADI202127262A patent/ECSP21027262A/es unknown
-
2024
- 2024-05-08 JP JP2024076157A patent/JP7741927B2/ja active Active
-
2025
- 2025-09-05 JP JP2025147403A patent/JP2025186315A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020061177A5 (enExample) | ||
| JP6924744B2 (ja) | Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用 | |
| JP2024009262A (ja) | Ｌｐａの遺伝子発現の阻害のための組成物及び方法 | |
| JP6752151B2 (ja) | 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー | |
| TWI881004B (zh) | 用於治療ｈｂｖ之靶向ｈｂｖ的治療性寡核苷酸及ｔｌｒ７促效劑之醫藥組合 | |
| TW201922264A (zh) | 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法 | |
| EA034924B1 (ru) | Олигомеры и олигомерные конъюгаты | |
| JP7697889B2 (ja) | アルファ－１アンチトリプシン欠乏症（ａａｔｄ）の治療法 | |
| JP6771387B2 (ja) | 遺伝子サイレンシング用トランスサイレチン対立遺伝子選択的ｕｎａオリゴマー | |
| JP2023538283A (ja) | 代謝症候群の治療のための組成物及び方法 | |
| JP2023536999A (ja) | Ｂ型肝炎患者のオリゴヌクレオチド処置 | |
| KR20240101580A (ko) | Hbv 치료를 위한 약학 조합물 | |
| JPWO2021188795A5 (enExample) | ||
| JP2025511854A (ja) | 非アルコール性脂肪肝疾患の治療 | |
| WO2026026776A1 (zh) | 抑制APP基因表达的siRNA及其缀合物和应用 | |
| CN116814620A (zh) | 用于抑制syn2a的多核苷酸、含有其的外泌体及其用途 | |
| JP2015532100A (ja) | アンフィレギュリンに特異的な二重鎖オリゴｒｎａ、そのような二重鎖オリゴｒｎａを含む二重鎖オリゴｒｎａの構造体及びこれを含む呼吸器疾患の予防または治療用の組成物 | |
| JP7788561B2 (ja) | アンチセンスオリゴヌクレオチド及びその使用 | |
| JPWO2021195467A5 (enExample) | ||
| JPWO2021252649A5 (enExample) | ||
| JPWO2022218941A5 (enExample) | ||
| JPWO2021126734A5 (enExample) | ||
| JP2023541170A (ja) | Ｚ－ａａｔタンパク質のレベルを低下させる方法 | |
| CN116670278A (zh) | 用于降低z-aat蛋白水平的方法 | |
| JPWO2022221430A5 (enExample) |